Understanding production helps explain why two vials labelled the same can be very different products — and why purity is the quiet variable behind most grey-market risk.
Two main ways to build a peptide
1. Solid-phase peptide synthesis (SPPS) — chemical assembly
Most short peptides (BPC-157, ipamorelin, the melanocortins, the nootropics) are built chemically, one amino acid at a time, on a tiny solid resin bead. Each amino acid's reactive sites are "protected" with chemical groups so they link only where intended; after each coupling, a group is removed to expose the next attachment point, and the cycle repeats. When the chain is complete it's cleaved off the resin and purified.
This is elegant but imperfect: every coupling step is slightly less than 100% efficient, so longer peptides accumulate truncated and mis-made byproducts that must be purified out. The purification step — typically high-performance liquid chromatography (HPLC) — is a major driver of cost and of the final product's actual purity.
2. Recombinant production — grown by cells
Larger or more complex peptides and proteins (insulin, IGF-1 analogues, and the backbones behind GLP-1 drugs) are often made recombinantly: the genetic instructions for the peptide are inserted into bacteria (often E. coli) or yeast, which are grown in large fermentation tanks and effectively turned into living factories that secrete the peptide. It's then harvested and purified. Modern GLP-1 drugs frequently combine a recombinant or synthetic backbone with extra chemical modifications (like a fatty-acid chain that extends how long the drug lasts).
Why this matters for you: the molecule is only half the story. A peptide's safety depends just as much on what else is in the vial — leftover synthesis byproducts, solvents, bacterial residues (endotoxins), or contaminants. A legitimate manufacturer proves purity with a Certificate of Analysis (COA) and third-party testing. Much grey-market material has neither, or has a COA that can't be verified — which is why we built a whole page on how to read one.
Where it's physically made
The active peptide ingredient (the "API") is produced at chemical-synthesis or biomanufacturing facilities — a large share globally is synthesised in China and India, then sold on as bulk powder. From there the path splits dramatically:
- Pharmaceutical route: API made under Good Manufacturing Practice (GMP), formulated, sterile-filled, and tested under regulatory oversight — this is what an approved drug or a licensed compounding pharmacy uses.
- Grey-market route: the same or lower-grade bulk powder is bought by a reseller, reconstituted or simply re-vialled, labelled "Research Use Only," and shipped to consumers — often with no sterility assurance and unverifiable purity.
The "drying" step: lyophilization
Most peptides you'd buy arrive as a small white or off-white cake or powder in a sealed vial. That's because peptides are fragile in water — they degrade — so they're lyophilized (freeze-dried) for stability. The process, in brief:
- Freezing. The peptide solution is frozen solid, often well below −40 °C, so the water becomes ice and the peptide is locked in place.
- Primary drying (sublimation). Under deep vacuum, the ice converts directly from solid to vapour without melting, pulling water out while leaving the delicate peptide structure intact.
- Secondary drying. Gentle warming removes the last tightly-bound moisture, leaving a dry, stable cake that can be stored and shipped.
To use a lyophilized peptide it must be reconstituted — dissolved back into a sterile liquid (commonly bacteriostatic water). This is a step where grey-market use goes wrong: non-sterile water, wrong volumes leading to wildly miscalculated doses, and contamination introduced at the kitchen counter rather than under a sterile hood.
A lyophilized cake tells you almost nothing about quality. It can look identical whether it contains exactly what the label says, a fraction of it, a different peptide, or impurities. Appearance is not purity. Only testing is.